Mr. Speaker, clearly we look at structural questions. We have to respond in an immediate way, but we have to approach this very serious question of the Ebola virus in a structural way and make sure that there is a sustained, progressive, and accessible approach that begins to change the social and economic conditions and ensure that people have access to health care.
I want to add one other point, and that is that right here in Ottawa, the Ottawa Hospital Research Institute itself has been doing a lot of research. When they wrote to the minister in the middle of August, they said:
We have constructed and commissioned a Virus-Manufacturing Suite that specializes in the production of pharmaceutical grade products very similar to the VSV-EBOV vaccine.
This is actually another initiative that could be taken up right here in Canada. I do not know where the government is on the Ottawa Hospital Research Institute and the incredible work it is doing. This is taking place right here in Canada, and the government needs to support it, because the development of a vaccine, of course, is very critical.